A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging ...

I am 78 years old and in fair health.

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Fecal microbiota ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...

A recurrence of C. diff is common after an initial episode, with about 20% of people having a recurrence. A recurrence is ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

WEST LAFAYETTE, Ind. – Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S. Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for ...